Indian generics bringing down global price of hepatitis C drugs, finds WHO - Hindustan Times
close_game
close_game

Indian generics bringing down global price of hepatitis C drugs, finds WHO

Hindustan Times | By, New Delhi
Sep 10, 2016 03:29 PM IST

India’s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc’s patent application was rejected in January 2015.

India’s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc’s patent application was rejected in January 2015.

Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug.(HTArchive)
Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug.(HTArchive)

Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.

Hindustan Times - your fastest source for breaking news! Read now.

“By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,” said Henk Bekedam, World Health Organisation (WHO) representative in India .

In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.

Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.

In India, 12 to 18 million people are infected by the disease.

WHO, which has sought fairer pricing of ‘unaffordable’ hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.

“No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,” WHO experts said.

Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.

It would amount to 10.5% of Netherlands’ annual drug budget, 190% for Poland, and 33% for the UK.

Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.

Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.

Natco and Hetero got the Drugs Controller General of India’s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.

Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away!- Login Now!
Stay informed on Business News along with Gold Rates Today, India News and other related updates on Hindustan Times Website and APPs
SHARE THIS ARTICLE ON
Share this article
  • ABOUT THE AUTHOR
    author-default-90x90

    Himani Chandna is a Delhi-based journalist covering the business of healthcare, pharmaceuticals, human resources and brands

SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Friday, March 29, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On